How We Supported a Biosimilar Launch That Achieved 15% Market Share in Year One

Launching a biosimilar in the U.S. market is one of the most demanding commercialization challenges in pharmaceutical marketing. Unlike traditional generics, biosimilars do not benefit from automatic pharmacy substitution, meaning every prescription must be actively won from prescribers and protected through payer contracts. When our client approached us with a biosimilar ready for FDA approval, the goal was clear: capture 15% market share within 12 months against an entrenched reference biologic that had dominated its therapeutic category for over a decade. We built a phased commercialization strategy that combined pre-launch physician education, payer access planning, and targeted digital outreach to reach that milestone ahead of schedule.

What Makes Biosimilar Commercialization Different from a Traditional Drug Launch?

Biosimilar launches sit in an unusual space between branded drug introductions and generic rollouts. A branded launch relies on clinical differentiation and new mechanism-of-action messaging. A generic launch depends on automatic substitution at the pharmacy counter and price advantage. Biosimilars get neither of those advantages by default. They must prove clinical equivalence to a reference biologic through rigorous FDA review, yet they still need to be actively marketed to physicians who may be skeptical about switching stable patients off a familiar therapy.

The competitive dynamics add another layer. Originator companies do not simply accept market share erosion. Many reference biologic manufacturers have maintained biosimilar defense teams for years, building relationships with prescribers and payers that make switching difficult. They often respond with aggressive rebating programs, patient copay assistance, and messaging campaigns designed to cast doubt on biosimilar quality. These are not theoretical barriers. They are the daily reality any biopharma marketing team faces during a biosimilar launch.

Key Differences Between Biosimilar and Traditional Drug Launches

Launch Factor	Traditional Branded Drug	Generic Drug	Biosimilar
Pharmacy Substitution	Not applicable	Automatic in most states	Requires interchangeability designation or active prescribing
Physician Education Needed	High (new mechanism)	Low	High (overcoming switching reluctance)
Payer Negotiation Complexity	High	Low	High (competing against originator rebates)
Typical Price Discount vs. Originator	Premium pricing	80-90% discount	15-35% discount at launch
Marketing Budget Relative to Originator	Comparable	Minimal	Significantly smaller

“Biosimilar launches demand the brand-building discipline of a branded drug launch combined with the cost-efficiency mindset of a generic. Most teams underestimate the originator’s willingness to fight for every prescription, and that miscalculation can stall market share growth before it starts.” – Strategy Team at Emulent Marketing

How Did We Structure the Pre-Launch Phase to Build Physician Confidence?

The pre-launch phase began 10 months before the anticipated FDA approval date. Our first priority was identifying the healthcare professionals (HCPs) who would have the greatest influence on early adoption. Rather than casting a wide net, we worked with our client’s medical affairs team to build a tiered target list based on prescribing volume for the reference biologic, geographic concentration of eligible patients, and each physician’s historical openness to biosimilar products in other categories.

Key opinion leader (KOL) engagement started early. We helped organize advisory boards where leading specialists could review the clinical equivalence data, ask questions directly to the medical science liaison (MSL) team, and discuss real-world switching protocols with peers who had experience using biosimilars in adjacent therapeutic areas. These were not promotional events. They were structured scientific exchanges designed to build familiarity and reduce the uncertainty that often prevents prescribers from writing that first biosimilar prescription.

Simultaneously, we developed a content strategy for the pharmaceutical brand that addressed the specific knowledge gaps our research had identified among target HCPs. The most common concerns were about immunogenicity differences, patient switching protocols, and what clinical monitoring (if any) was needed after transitioning a stable patient from the reference biologic.

Pre-launch activities and their strategic purpose:

• KOL Advisory Boards: Brought together 15-20 high-prescribing specialists per session to review switching data, surface objections, and create peer-validated talking points that MSLs could reference in later one-on-one conversations.
• Disease State Education Campaigns: Published unbranded educational content about biosimilar science and regulatory standards, reaching prescribers before the brand name was even public. This primed the audience to think about biosimilars as a category, not just a single product.
• MSL Field Mapping: Assigned medical science liaisons to geographic territories based on patient concentration data, so that by launch day, every top-decile prescriber had already had at least one scientific exchange about the product’s clinical profile.
• Payer Pre-Engagement: Initiated conversations with pharmacy benefit managers (PBMs) and health plan medical directors six months before launch, presenting health economic models showing total cost of care reductions for plans that placed the biosimilar on preferred formulary tiers.

What Payer Access Strategy Did We Use to Secure Formulary Placement?

Winning formulary access is where many biosimilar launches stumble. A product can have strong clinical data, positive KOL endorsement, and a competitive price, yet still fail to gain meaningful market share if payers do not create a pathway for prescribers to choose it easily. The originator’s advantage here is significant: years of established rebate contracts, patient support programs, and prior authorization protocols that default to the reference biologic.

Our payer access strategy centered on three pillars. First, we developed a health economics and outcomes research (HEOR) package that went beyond simple per-unit price comparisons. We modeled total cost of care scenarios showing how the biosimilar’s pricing, combined with reduced administrative burden from simplified prior authorization, could save plans between 18% and 26% per patient per year compared to the reference biologic. These models were customized for different plan types, including commercial plans, Medicare Advantage, and integrated delivery networks.

Second, we worked closely with our client’s market access team to structure contracts that gave payers confidence. This included performance guarantees tied to switching success rates and patient adherence metrics. Payers who were reluctant to disrupt their existing originator contracts responded well to outcomes-based agreements that reduced their perceived risk.

Third, we built targeted digital campaigns aimed at pharmacy directors and formulary committee members. These campaigns delivered clinical comparison data, HEOR summaries, and peer-reviewed publications through channels where these decision-makers actually consumed professional content, including medical journal advertising, targeted email sequences, and sponsored content on pharmacy trade platforms.

Formulary Placement Results by Plan Type After 12 Months

Plan Type	Target Formulary Tier	Achieved Placement Rate	Average Time to Placement
Commercial (large employer)	Preferred specialty	68%	4.2 months
Medicare Advantage	Preferred specialty	54%	6.1 months
Integrated Delivery Networks	First-line preferred	72%	3.8 months
PBM National Formularies	Preferred with step edit	61%	5.5 months

“Payer conversations should start long before launch day. The biosimilar brands that wait until after FDA approval to begin formulary discussions are already months behind the originator’s established rebate infrastructure. Early engagement with customized HEOR models shifts the conversation from ‘why switch’ to ‘how quickly can we switch.'” – Strategy Team at Emulent Marketing

How Did Targeted HCP Engagement Drive Early Prescribing Adoption?

Once the product received FDA approval, our marketing execution shifted from education to activation. The goal was converting the awareness and confidence we had built during the pre-launch phase into actual prescriptions. This required a coordinated approach across digital channels, field sales, and medical affairs that delivered the right message to the right physician at the right moment in their decision-making process.

We segmented HCPs into three behavioral groups based on their likely response to the biosimilar. The first group, which we called “early movers,” were physicians who had already used biosimilars in other therapeutic areas and needed only clinical data and formulary confirmation to begin prescribing. The second group, “cautious evaluators,” were open to biosimilars conceptually but wanted to see peer adoption data and patient outcomes before committing. The third group, “originator loyalists,” had strong relationships with the reference biologic’s sales team and would require sustained engagement over multiple quarters.

For each segment, we created distinct messaging tracks and channel strategies. Early movers received streamlined clinical comparison materials and direct access to a dedicated account manager who could resolve formulary and prior authorization questions in real time. Cautious evaluators received case-based content showing real-world switching outcomes from early adopter practices, delivered through email nurture sequences and targeted digital advertising on medical education platforms. Originator loyalists were engaged primarily through MSL-led scientific exchanges and peer-to-peer speaker programs featuring KOLs who had already transitioned patients successfully.

HCP segmentation and engagement approach:

• Early Movers (approximately 20% of target list): These prescribers had prior biosimilar experience and were ready to act once formulary access was confirmed. Our approach focused on removing friction: fast-track prior authorization support, clinical comparison one-pagers, and direct account manager access to resolve logistical questions within 24 hours.
• Cautious Evaluators (approximately 50% of target list): The largest group needed social proof and practical switching guidance. We delivered monthly email updates with de-identified patient switching outcome data, hosted virtual grand rounds with early adopter physicians, and created a switching protocol toolkit that prescribers could implement in their own practices.
• Originator Loyalists (approximately 30% of target list): This segment required the longest engagement timeline. MSLs led with published clinical equivalence data and third-party pharmacovigilance reports. We paired this with health economics presentations tailored to each practice’s patient population and payer mix.

“Treating all prescribers the same is the fastest way to waste a biosimilar marketing budget. The physician who has already prescribed three other biosimilars needs a completely different conversation than the one who has never switched a patient off a reference biologic. Segmentation based on behavior, not just specialty, is what separates successful launches from mediocre ones.” – Strategy Team at Emulent Marketing

What Digital Marketing Tactics Moved the Needle on Brand Awareness and Prescribing?

Biosimilar brands typically operate with marketing budgets that are a fraction of what the originator spends. That constraint forced us to be extremely precise about where every dollar went. We built a digital marketing program designed around measurable physician engagement signals rather than broad reach metrics like impressions or clicks.

Our digital program operated across four primary channels. Point-of-care messaging through electronic health record (EHR) integrations reached prescribers at the exact moment they were making treatment decisions for eligible patients. Programmatic advertising on medical education platforms like Medscape and Doximity delivered branded content to verified HCPs based on specialty, prescribing history, and geographic location. Email campaigns segmented by our behavioral groups delivered progressively detailed content, from disease-state awareness through branded clinical data to formulary-specific prescribing guides. Finally, peer-to-peer video content featuring KOLs discussing their switching experience was distributed through both organic social channels and paid promotion on professional networks.

The competitive audit we conducted at the outset revealed that the originator was spending heavily on direct-to-consumer awareness campaigns and physician office visits through a large field sales force. Our client could not match that spending, so we focused on channels where precision targeting and content relevance could outperform raw volume. EHR-based messaging, for example, achieved engagement rates three to four times higher than traditional journal advertising at roughly one-fifth the cost per engaged physician.

Digital Channel Performance Comparison (First 12 Months)

Channel	Physicians Reached	Engagement Rate	Cost Per Engaged HCP	Attributed Rx Lift
EHR Point-of-Care Messaging	4,200	18.3%	$42	+12% script volume
Medical Platform Programmatic Ads	8,500	6.1%	$78	+7% script volume
Segmented Email Campaigns	3,800	22.7%	$18	+9% script volume
KOL Peer-to-Peer Video	2,100	31.4%	$95	+15% script volume

How Did We Handle the Originator’s Competitive Response?

No biosimilar launch plan survives first contact with the originator’s defense strategy unchanged. Within the first 60 days of our launch, the reference biologic manufacturer responded with three predictable but forceful moves: enhanced rebates to payers who maintained preferred status for the originator, a copay assistance program that eliminated out-of-pocket costs for patients already on the reference product, and increased field sales visits to the same high-prescribing physicians we were targeting.

We had anticipated each of these responses during our brand strategy development phase, which allowed us to deploy counter-strategies quickly rather than reactively. When the originator increased rebates, we worked with our client’s market access team to present payers with long-term total cost of care projections showing that the originator’s rebate-inflated pricing still resulted in higher net costs over a 24-month period. When the copay assistance program launched, we countered with patient education materials explaining that copay cards do not reduce the overall cost burden to their health plan, and that biosimilar coverage often meant lower long-term out-of-pocket exposure as plan designs evolved.

The field sales escalation was the most challenging response to counter, given our smaller commercial team. We addressed this by focusing our field representatives on accounts where we had already secured formulary preference, concentrating resources where conversion was most likely rather than spreading thin across the entire prescriber universe. MSLs continued to engage originator-loyal physicians through scientific channels, maintaining a steady presence without the promotional intensity that would trigger physician resistance.

Competitive response timeline and counter-strategies:

• Days 1-30 (Originator Enhanced Rebating): Responded with customized HEOR models for each major payer showing net cost advantage over originator even after rebate adjustments. Secured commitment from three national PBMs to maintain preferred biosimilar positioning based on total cost evidence.
• Days 30-60 (Originator Copay Assistance Expansion): Launched patient education campaign through specialty pharmacy partners explaining biosimilar coverage benefits. Created comparison tools showing long-term cost exposure under different coverage scenarios that patients and care teams could review together.
• Days 60-120 (Originator Field Sales Escalation): Concentrated our field team on formulary-advantaged accounts. Deployed digital retargeting campaigns to physicians who had engaged with our content but had not yet written a prescription. Activated KOL-led speaker programs in the five metro areas with highest eligible patient concentration.

What Were the Results After 12 Months, and What Drove Them?

At the 12-month mark, the biosimilar had captured 15.2% market share of the reference biologic’s total prescription volume, exceeding the initial target. That number tells only part of the story. The trajectory of market share growth was equally telling: the first three months accounted for just 4.1% market share as formulary placements were still being finalized, followed by acceleration to 9.8% at month six once major payer contracts activated, and then steady growth through months seven through twelve as physician confidence and patient switching volumes increased.

Several factors drove these results beyond what competitors in similar biosimilar launches had achieved during the same period. First, the pre-launch investment in KOL relationships and MSL territory mapping meant that our client’s medical affairs presence was already established when the commercial team activated. Second, the behavioral segmentation of our HCP target list allowed us to allocate marketing spend toward physicians most likely to convert, rather than distributing resources evenly across all targets. Third, the payer access strategy’s emphasis on outcomes-based contracting gave health plans a reason to proactively steer prescribing toward our client’s biosimilar rather than passively waiting for physicians to request it.

Market Share Growth Timeline

Time Period	Cumulative Market Share	Primary Growth Driver
Month 1-3	4.1%	Early mover prescribers and integrated delivery network contracts
Month 4-6	9.8%	Major PBM formulary activations and commercial plan placements
Month 7-9	12.6%	Cautious evaluator conversion driven by peer-to-peer programs
Month 10-12	15.2%	Medicare Advantage placements and expanded specialty pharmacy distribution

“The biosimilar brands that reach meaningful market share in year one are the ones that treat launch as a 18-month program, not a launch-day event. The pre-launch work on physician education, payer contracting, and competitive scenario planning is what creates the conditions for rapid post-approval growth. By the time the FDA approval comes through, the market should already be prepared to receive the product.” – Strategy Team at Emulent Marketing

What Can Other Pharmaceutical Brands Learn from This Biosimilar Launch?

This biosimilar launch reinforced several principles that apply broadly across life sciences marketing and pharmaceutical commercialization. The most transferable lessons fall into areas that any brand team can act on, regardless of therapeutic category or competitive intensity.

Transferable principles from this launch:

• Start Payer Conversations Before Regulatory Approval: Health plans need time to evaluate, model, and implement formulary changes. Brands that wait until post-approval to begin these discussions lose months of potential market share growth while competitors maintain their default positioning.
• Segment Prescribers by Behavior, Not Just Demographics: Specialty and prescribing volume are starting points, but the real differentiator is a physician’s behavioral readiness to adopt. A rheumatologist who already uses three biosimilars needs a fundamentally different conversation than one who has never switched a patient.
• Build Your Competitive Response Plan Before You Need It: Originator defense strategies are predictable. Plan your counter-moves in advance so that when enhanced rebates, copay programs, or field sales escalations arrive, your team can respond within days rather than weeks.
• Invest in Point-of-Care Digital Channels: For biosimilars with constrained marketing budgets, EHR-based messaging and targeted medical platform advertising deliver better physician engagement per dollar than traditional journal advertising or broad programmatic campaigns.
• Track Leading Indicators, Not Just Market Share: Monthly market share data arrives with a lag. Track weekly prescribing trends by HCP segment, formulary win rates by plan type, and digital engagement by content type to identify problems and opportunities while you can still act on them.

The trends shaping life sciences marketing continue to push toward more precise, data-informed commercialization approaches. As the U.S. biosimilar market matures and more products compete within each therapeutic class, the brands that invest in structured pre-launch preparation, behavioral audience segmentation, and integrated payer and provider strategies will continue to capture disproportionate market share.

Conclusion

Achieving 15% market share in a biosimilar’s first year requires coordination across medical affairs, market access, commercial marketing, and digital channels that most teams underestimate. The work starts well before FDA approval and continues through every phase of competitive response and physician adoption. At Emulent, we bring this level of strategic planning and execution to pharmaceutical marketing programs for biosimilar, biologic, and specialty pharmaceutical brands. If your organization is preparing for a biosimilar launch or looking to accelerate market share growth for an existing product, contact the Emulent team to discuss how we can support your pharmaceutical marketing goals.